RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment

Mol Cancer. 2021 Aug 21;20(1):107. doi: 10.1186/s12943-021-01399-3.

Abstract

Background: Necroptosis is emerging as a new target for cancer immunotherapy as it is now recognized as a form of cell death that increases tumor immunogenicity, which would be especially helpful in treating immune-desert tumors. De novo synthesis of inflammatory proteins during necroptosis appears especially important in facilitating increased anti-tumor immune responses. While late-stage transcription mediated by NF-κB during cell death is believed to play a role in this process, it is otherwise unclear what cell signaling events initiate this transactivation of inflammatory genes.

Methods: We employed tandem-affinity purification linked to mass spectrometry (TAP-MS), in combination with the analysis of RNA-sequencing (RNA-Seq) datasets to identify the Tripartite Motif Protein 28 (TRIM28) as a candidate co-repressor. Comprehensive biochemical and molecular biology techniques were used to characterize the role of TRIM28 in RIPK3 activation-induced transcriptional and immunomodulatory events. The cell composition estimation module was used to evaluate the correlation between RIPK3/TRIM28 levels and CD8+ T cells or dendritic cells (DC) in all TCGA tumors.

Results: We identified TRIM28 as a co-repressor that regulates transcriptional activity during necroptosis. Activated RIPK3 phosphorylates TRIM28 on serine 473, inhibiting its chromatin binding activity, thereby contributing to the transactivation of NF-κB and other transcription factors, such as SOX9. This leads to elevated cytokine expression, which then potentiates immunoregulatory processes, such as DC maturation. The expression of RIPK3 has a significant positive association with the tumor-infiltrating immune cells populations in various tumor type, thereby activating anti-cancer responses.

Conclusion: Our data suggest that RIPK3 activation-dependent derepression of TRIM28 in cancer cells leads to increased immunostimulatory cytokine production in the tumor microenvironment, which then contributes to robust cytotoxic anti-tumor immunity.

Keywords: Chromatin; Immunostimulatory cytokines; NF-κB; RIPK3; TRIM28; Transcriptional regulator.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Binding Sites
  • Cell Death
  • Cell Line
  • Cytokines / metabolism
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Mice
  • Models, Biological
  • NF-kappa B / metabolism
  • Necroptosis
  • Neoplasms / genetics
  • Neoplasms / metabolism
  • Protein Binding
  • Receptor-Interacting Protein Serine-Threonine Kinases / metabolism*
  • Signal Transduction
  • Tripartite Motif-Containing Protein 28 / genetics*
  • Tumor Microenvironment / genetics*

Substances

  • Cytokines
  • NF-kappa B
  • TRIM28 protein, human
  • Tripartite Motif-Containing Protein 28
  • RIPK3 protein, human
  • Receptor-Interacting Protein Serine-Threonine Kinases